Accretion Pharmaceuticals Limited (NSE:ACCPL)
India · Delayed Price · Currency is INR 169.90
+6.90 (4.23%)
At close: Jul 31, 2026
Accretion Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 40.21 | 0.51 | 0.92 | 0.36 | 3.75 |
Cash & Short-Term Investments | 40.21 | 0.51 | 0.92 | 0.36 | 3.75 |
Cash Growth | 7814.57% | -44.60% | 151.92% | -90.28% | - |
Accounts Receivable | 224 | 116.61 | 58.05 | 57.99 | 40.68 |
Other Receivables | - | 7.88 | 9.85 | - | - |
Receivables | 279.41 | 124.86 | 68.58 | 57.99 | 40.68 |
Inventory | 283.75 | 206.1 | 144.76 | 77.64 | 69.33 |
Other Current Assets | 2.57 | 2.79 | 5.71 | 9.29 | 5.05 |
Total Current Assets | 605.93 | 334.25 | 219.96 | 145.28 | 118.8 |
Property, Plant & Equipment | 134.14 | 38.6 | 36.29 | 60.12 | 58.36 |
Other Long-Term Assets | 25.66 | 25.14 | 18.14 | 0.39 | 0.26 |
Total Assets | 766.56 | 398.74 | 274.39 | 205.8 | 177.41 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 15.89 | 18.39 | 16.4 | 78.5 | 67.37 |
Accrued Expenses | - | 0.73 | 0.22 | 0.15 | 0.13 |
Short-Term Debt | 114.59 | 93.9 | 41.56 | 37.4 | 22.26 |
Current Portion of Long-Term Debt | - | 35.46 | 24.11 | 18.59 | 24.83 |
Current Income Taxes Payable | - | 25.99 | 18.6 | 0.6 | 0.25 |
Other Current Liabilities | 77.65 | 57.79 | 49.46 | 3.05 | 2.47 |
Total Current Liabilities | 208.12 | 232.26 | 150.34 | 138.28 | 117.31 |
Long-Term Debt | 8.63 | 11.68 | 69.11 | 28.67 | 28.99 |
Pension & Post-Retirement Benefits | - | - | - | 0.44 | 0.34 |
Long-Term Deferred Tax Liabilities | 2.72 | 1.95 | 0.01 | -0.02 | 0.02 |
Other Long-Term Liabilities | - | - | - | - | 0 |
Total Liabilities | 219.47 | 245.88 | 219.46 | 167.37 | 146.65 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 111.16 | 81.7 | 40 | 38.43 | 30.76 |
Retained Earnings | 435.93 | 71.17 | 14.93 | - | - |
Shareholders' Equity | 547.09 | 152.87 | 54.93 | 38.43 | 30.76 |
Total Liabilities & Equity | 766.56 | 398.74 | 274.39 | 205.8 | 177.41 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 123.21 | 141.04 | 134.78 | 84.66 | 76.08 |
Net Cash (Debt) | -83.01 | -140.53 | -133.86 | -84.29 | -72.33 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -7.75 | -17.53 | -17.61 | - | - |
Filing Date Shares Outstanding | 11.1 | 8.17 | 8.17 | - | - |
Total Common Shares Outstanding | 11.1 | 8.17 | 7.6 | - | - |
Working Capital | 397.81 | 102 | 69.62 | 7 | 1.49 |
Book Value Per Share | 49.27 | 18.71 | 7.23 | - | - |
Tangible Book Value | 547.09 | 152.87 | 54.93 | 38.43 | 30.76 |
Tangible Book Value Per Share | 49.27 | 18.71 | 7.23 | - | - |
Land | - | 4.8 | 4.8 | 4.8 | 4.8 |
Buildings | - | - | - | 21.02 | 20.12 |
Machinery | - | 43.78 | 33.73 | 51.64 | 41.54 |